For decades, polycystic ovary syndrome has been recognized as one of the most common hormonal disorders in women, affecting approximately one in eight globally. Yet despite its prevalence, the name itself has long been considered misleading. The term implies the presence of ovarian cysts, which are not actually a defining feature of the condition. More importantly, it obscures the disorder's true nature as a complex endocrine and metabolic condition with impacts far beyond the reproductive system.

Now, after an unprecedented global consensus process involving thousands of patients and health professionals from every continent, the condition has a new name: polyendocrine metabolic ovarian syndrome, or PMOS. The change represents more than a semantic update. It reflects a fundamental shift in how the medical community understands and communicates about a condition that affects roughly 170 million women during their reproductive years alone.

Why the Old Name Fell Short

The problems with the name polycystic ovary syndrome have been apparent for years. The term polycystic ovary suggests pathological cysts on the ovaries, yet these are not increased in people with the condition. What ultrasound imaging actually reveals is arrested follicular development, a distinctly different phenomenon involving small antral follicles that accumulate rather than mature properly.

Beyond the technical inaccuracy, the narrow reproductive focus of the name has contributed to widespread confusion, delayed diagnosis, and fragmented care. Studies show that up to 70 percent of affected individuals remain undiagnosed. Many report dissatisfaction with the information they receive and the quality of care available to them. The name has also reinforced stigma, particularly in cultures where fertility carries significant social value, causing distress for many who carry the diagnosis.

The condition encompasses far more than ovarian dysfunction. It involves disturbances across multiple hormone systems, metabolic complications including insulin resistance and type 2 diabetes risk, cardiovascular disease risk, psychological impacts such as depression and anxiety, and dermatological features like excess hair growth and acne. Yet the old name captured none of this complexity.

Building a Global Consensus

Previous attempts to rename the condition had stalled repeatedly, hampered by a lack of coordinated international leadership, disagreement on an alternative name, and the absence of a comprehensive implementation strategy. This time, the effort was different.

Funded by the Australian National Health and Medical Research Council, the initiative was led by a partnership between an Australian research center, the Androgen Excess and Polycystic Ovary Syndrome Society, and Verity, a patient advocacy organization based in the United Kingdom. The steering committee included patient representatives and multidisciplinary health professionals from three continents.

The process engaged 56 organizations spanning patient advocacy groups and professional societies across obstetrics and gynecology, endocrinology, fertility medicine, primary care, nutrition, dermatology, and other disciplines. The goal was to ensure broad representation across world regions and specialties, with particular attention to including voices from underrepresented populations.

Two global surveys conducted in 2025 and 2026 generated 14,360 responses from patients and health professionals across all world regions. The surveys were provided in English, Chinese, German, Persian, and Malaysian to maximize reach. Questions addressed naming principles such as scientific accuracy, ease of communication, avoidance of stigma, and cultural appropriateness. Respondents also weighed different approaches, including adopting a generic name like diabetes or asthma, retaining the acronym with different terms, or creating an entirely new symptom based name.

Workshops and Iterative Refinement

Two international consensus workshops brought together approximately 90 representatives, including patient advocates and leading health professionals from diverse disciplines and world regions. Recruitment was rigorous and purposive, with invitations extending to governing bodies of engaged societies, self nominated participants from the surveys, and targeted outreach to ensure balanced representation.

Before the first workshop, all participants signed a code of conduct covering expected behaviors, confidentiality, and agreement to respect publication timelines and coordinated messaging. Breakout groups were carefully structured to include participants from multiple world regions, several patients, and representatives from at least three health disciplines. Each group was co chaired by a patient and a health professional, with independent observers present to ensure adherence to agreed upon norms.

The workshops used a structured consensus method. Survey results were presented to establish the foundation. Participants then engaged in facilitated breakout discussions where each person had timed opportunities to raise clarifications, concerns, or considerations. After discussions, confidential online voting was conducted to rank priorities. The process was repeated as terms were combined to form candidate names.

Survey results showed strong support for several guiding principles. Scientific accuracy was endorsed by 86 percent of health professionals and 60 percent of patients. Ease of communication received 85 percent and 62 percent support respectively. Avoidance of stigma was particularly important to patients, with 66 percent prioritizing it compared to 85 percent of health professionals. Cultural appropriateness was supported by 80 percent of health professionals and 53 percent of patients.

The preferred approach, endorsed by 86 percent of patients and 70 percent of health professionals, was to adopt a new, symptom based name that accurately reflects the condition's features. This was prioritized over keeping the old acronym with new terms or adopting a generic name.

Choosing the Right Terms

Selecting the specific terms proved challenging. For the endocrine component, both endocrine and polyendocrine received strong support. Polyendocrine ultimately prevailed because it more accurately captures the involvement of multiple hormone systems, including insulin, androgens, neuroendocrine pathways, and ovarian hormones.

The metabolic term was strongly supported throughout, reflecting the condition's fundamental metabolic underpinnings. Insulin resistance affects approximately 85 percent of those with the condition, including 75 percent of lean women. This metabolic dysfunction drives androgen excess and contributes to complications including impaired glucose tolerance, gestational diabetes, type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease. Evidence shows that women with the condition face increased odds of composite cardiovascular disease, myocardial infarction, and stroke compared to those without it.

The reproductive term sparked the most debate. While reproductive accurately aligned with the condition's genetic origins, pathophysiology, and clinical features, participants recognized potential for social stigmatization in some cultures. Ovulatory was considered less stigmatizing but too narrow, failing to encompass broader reproductive features and becoming irrelevant after menopause.

A second survey and workshop were needed to resolve this question. The term ovarian emerged as the consensus choice, capturing endocrine, follicular, and ovulatory disturbances in a single word while avoiding the cultural concerns associated with reproductive. Importantly, ovarian avoids the misleading reference to cysts that plagued the original name.

One proposed combination, endocrine metabolic ovulatory syndrome, was excluded because its acronym would spell EMOS, which overlaps with a youth subculture centered on emotional expression, melancholy, and anxiety. Such an association would undermine the goal of reducing stigma and confusion.

The final name, polyendocrine metabolic ovarian syndrome, received support from 69 percent of patients and 57 percent of health professionals in the last survey, and was endorsed by all but two participants in the final workshop.

Scientific Justification

The new name aligns with current scientific understanding. Large scale genomic analyses confirm that the condition has polygenic origins across neuroendocrine, metabolic, and reproductive pathways. Hyperandrogenism, a defining diagnostic feature, results from elevated ovarian and often adrenal androgens. Central neuroendocrine abnormalities include increased gonadotropin releasing hormone pulsatility, which elevates luteinizing hormone and drives excessive ovarian androgen production.

Insulin resistance and compensatory hyperinsulinemia amplify androgen secretion and disrupt steroidogenesis, highlighting the metabolic endocrine interplay. Altered concentrations of anti Müllerian hormone, changes in ovarian endocrine function, and disturbances in adipokine signaling and gut hormone interactions all influence clinical features.

Ovarian dysfunction itself has genetic origins and involves disturbances in endocrine and paracrine function. Neuroendocrine abnormalities disrupt ovarian steroidogenesis and impair follicular maturation. Hyperinsulinemia driven dysregulation of granulosa and theca cells worsens hyperandrogenism. These abnormalities disrupt folliculogenesis and result in accumulation of small antral follicles, the classic ultrasonographic appearance. Elevated anti Müllerian hormone occurs with disordered folliculogenesis and is now included in adult diagnostic criteria. Clinically, these disturbances manifest as ovulatory dysfunction, menstrual irregularity, and infertility.

Implementation Strategy

Renaming a medical condition requires more than consensus. It demands a coordinated implementation strategy to support adoption across health systems, research institutions, education providers, clinical guidelines, and disease classification systems.

The implementation plan unfolds in eight stages. First, publication of the official announcement is supported by commentaries, clinical reviews, and updates to textbooks and educational materials. Second, patient and health professional resources are being co designed in multiple languages for diverse platforms. Third, a structured communication strategy includes society toolkits, multilingual resources, multimedia dissemination, and coordinated events worldwide.

Fourth, the new terminology will be incorporated into electronic health records, including the Systematized Nomenclature of Medicine Clinical Terms, with engagement of major electronic medical record vendors and key stakeholders in health care provider education. Fifth, governments, research funders, journal editors, regulators, and the pharmaceutical industry are being engaged to support adoption across research classifications, publication processes, and funding systems.

Sixth, formal engagement with international bodies, including the World Health Organization, will progress integration into disease classification systems such as the International Classification of Diseases. Seventh, a managed transition period of three years includes monitoring and evaluation, with consideration of emerging evidence on subtypes and refinement of terminology as scientific understanding evolves. Finally, the new name will be integrated into the International Guideline, already used in 195 countries, during its next update in 2028.

Marketing specialists contributed pro bono analysis, recommending an evolutionary rebranding approach that supports continuity with the existing name rather than revolutionary rebranding that would imply a completely new condition. The similarity between PCOS and PMOS serves this evolutionary strategy while correcting the fundamental inaccuracies of the old name.

A Model for Medical Nomenclature

The process exemplifies how medical terminology can evolve to keep pace with scientific understanding. It demonstrates the value of inclusive stakeholder engagement, robust consensus methods, and careful attention to implementation from the outset.

Limitations of the initiative include disproportionate representation across world regions, with lower participation from middle income and low income countries and from Asia, Africa, and South America. The use of purposive, non probability sampling and voluntary participation could introduce selection bias. However, analysis of survey results by region did not identify major differences in final term or name preferences.

The overwhelming majority of participants supported the name change and endorsed the principles, approach, and terms selected. Only two workshop participants remained opposed, citing concerns about evolving genetic science, the potential for a male phenotype, and rebranding challenges.

For the millions affected by the condition now known as polyendocrine metabolic ovarian syndrome, the new name offers more than semantic precision. It promises greater awareness, faster diagnosis, better quality care, and reduced stigma. By aligning nomenclature with scientific reality, the change strengthens the foundation for research, policy, advocacy, and ultimately, improved health outcomes globally.

Credit & Disclaimer: This article is a popular science summary written to make peer-reviewed research accessible to a broad audience. All scientific facts, findings, and conclusions presented here are drawn directly and accurately from the original research paper. Readers are strongly encouraged to consult the full research article for complete data, methodologies, and scientific detail. The article can be accessed through https://doi.org/10.1016/S0140-6736(26)00717-8

Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.